Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 15 March 1996:
Vol. 271. no. 5255, p. 1490
DOI: 10.1126/science.271.5255.1490
Prev | Table of Contents | Next

News & Comment

Robert Koenig

Berlin--The announcement last week that the Swiss drug giants Sandoz and Ciba-Geigy plan to merge is the latest in a series of consolidations that is changing the face of the world's pharmaceutical industry. The two companies last year spent a total of more than $2 billion on R&D. The new joint company, to be called Novartis, is expected to be a force in genome-related research, although some pruning of overlapping research is expected.




To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)